EU approves Kyowa Kirin’s drug for rare lymphomaThe European Commission has approved Poteligeo (mogamulizumab), a treatment for rare types of non-Hodgkin’s lymphoma. The drug is Share XEU approves Kyowa Kirin’s drug for rare lymphomahttps://pharmaphorum.com/news/eu-approves-kyowa-kirins-drug-for-rare-lymphoma/
Celltrion/Teva Rituxan biosimilar edges closer to US approvalIt looks increasingly likely that Roche’s cancer blockbuster Rituxan (rituximab) will face competition from a cheaper biosimilar in Share XCelltrion/Teva Rituxan biosimilar edges closer to US approvalhttps://pharmaphorum.com/news/celltrion-teva-rituxan-biosimilar-edges-closer-to-us-approval/
Great news for Kite after CAR-T success in cancer patientsKite looks all set for a regulatory approval later this year for its CAR-T drug KTE-CI9 after the Share XGreat news for Kite after CAR-T success in cancer patientshttps://pharmaphorum.com/news/good-news-kites-car-t-drug-lymphoma/
